ESMO Research Fellowships - Translational Focus 2020
Molecular classification of pancreatic cancer by gene expression analysis of circulating tumor DNA
Fellow: Elisabeth Bergen
Home institute: Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, Austria
Host institute: Department of Gastroenterology and Gastrointestinal Oncology Department Georges Pompidou European Hospital, Sorbonne Paris-Cité, Université Paris-Descartes, Paris, France
Sponsor: ESMO
ENSURE study - Dendritic cell therapy combined with surgery in mesothelioma
Fellow: Luca Cantini
Home institute: Università Politecnica delle Marche - AOU Ospedali Riuniti Ancona, Ancona, Italy
Host institute: Erasmus MC Cancer Centre, Rotterdam, Netherlands
Sponsor: ESMO
The role of tumor-specific CD8+ T cells in tumor evolution and response to immune checkpoint inhibitors in cervical cancer patients.
Fellow: Giulia Costanza Leonardi
Home institute: Università degli Studi di Catania, Catania, Italy
Host institute: Cancer Research Center of Toulouse (CRCT, Inserm UMR 1037) and Institut Universitaire du Cancer de Toulouse – Oncopole (IUCT-O), Toulouse, France
Sponsor: ESMO
Investigating the molecular mechanisms that regulate human breast cancer stem cell function in response to systemic therapy
Fellow: Long Nguyen
Home institute: Princess Margaret Cancer Centre, Toronto, Canada
Host institute: Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
Sponsor: ESMO
Impact of microbiota on breast cancer prognosis and treatment efficacy
Fellow: Andri Papakonstantinou
Home institute: Karolinska Institutet, Solna, Sweden
Host institute: Vall d’Hebron Institute of Oncology, Barcelona, Spain
Sponsor: ESMO
Prognostic and therapeutic significance of treatment-induced intrinsic subtypes and genomic changes in Luminal breast tumors
Fellow: Francesco Schettini
Home institute: Azienda Ospedaliera Universitaria Federico II, Naples, Italy
Host institute: August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain
Sponsor: ESMO
Characterisation of appendiceal adenocarcinoma by transcriptomic analysis and correlation with clinical outcomes: a step towards rational therapeutics
Fellow: Madeleine Strach
Home institute: Chris O'Brien Lifehouse, Lilyfield, Australia
Host institute: The Christie Colorectal and Peritoneal Oncology Research Group, Manchester Cancer Centre, Manchester, United Kingdom
Sponsor: ESMO
ESMO Research Fellowships - Clinical Focus 2020
Concurrent chemotherapy and PROton therapy coMpared to photon therapy, followed by Durvalumab maintEnance in sTagE III NOn-Small Cell Lung Cancer (NSCLC) (PROMETEO study): immunological and hematological effects.
Fellow: Francesco Cortiula
Home institute: CRO Aviano National Cancer Institute, Udine, Italy
Host institute: Maastricht University Medical Center+, Maastricht, Netherlands
Sponsor: ESMO
A prospective observational study to identify a composite biomarker for prediction and early detection of immunotherapy-related adverse events (irAEs)
Fellow: Aljosja Rogiers
Home institute: Melanoma Institute Australia, Sydney, Australia
Host institute: The Royal Marsden NHS Foundation Trust, London, United Kingdom
Sponsor: ESMO